Phase 3Active, not recruiting
A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP)
A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou (Academic or other)
- Enrolment
- 680 enrolled
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Cisplatin; Nivolumab; RT
- Ages
- adults, older adults
- Registry
- NCT03576417
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to determine the efficacy of nivolumab + cisplatin-RT relative to standard of care (SOC) cisplatin-RT alone, using the disease-free survival (DFS by investigator imaging assessment) as primary endpoint )
Primary outcomes
- Disease free survival
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered